Skip to content

Artificial Shrinkage for Human Blastocyst Prior Vitrification

Removal of Blastocoel Fluid Before Blastocyst Vitrification by Laser Pulse and Its Effect on Clinical Outcomes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02976662
Acronym
AS
Enrollment
100
Registered
2016-11-29
Start date
2016-09-30
Completion date
2017-12-31
Last updated
2016-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitrification

Brief summary

Investigators aim to investigate the effect of elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.

Detailed description

Human blastocyst formation begins about 5 days after injecting a single sperm into an oocyte in ICSI cycle or incubation of them in IVF cycle. Human blastocyst consists of cells forming an outer layer called trophotoderm that will form the placenta in case of successful implantation, an inner cell mass which become the fetus, a fluid-filled blastocoel cavity in the center, and a surrounding zone pellucida from which the embryo hatches to implant in the uterus. Human blastocyst contains a large amount of liquid in the blastocoel, which alters the infiltration of vitrification solution during the vitrification procedures leading to ice crystal formation. Therefore, investigators need to compare blastocyst survival, clinical pregnancy and implantation rates between vitrified untreated expanded blastocysts and vitrified blastocysts with artificially eliminated blastocoels by a laser pulse prior to vitrification

Interventions

Artificially eliminated blastocoelic fluid before vitrification procedures.

Sponsors

Benha University
CollaboratorOTHER
Dar AlMaraa Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* BMI of ≤ 32

Exclusion criteria

* Non-expanded blastocysts. * Women who had uterine pathology or abnormality.

Design outcomes

Primary

MeasureTime frameDescription
Implantation rate1 monthnumber of intrauterine gestational sacs over the total number of embryos transferred

Countries

Egypt

Contacts

Primary ContactYasmin Magdi, M.Sc
yas.magdi@hotmail.com+201282313979

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026